RxDoctor Payments Data

Heather Matthews

Family · The Woodlands, TXNPI 1598153868

Payments from drug & device makers

$12,576in general payments, 2019–2025

Across 510 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$882
  • Amgen$803
  • AbbVie$621
  • Corcept Therapeutics$547
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,37511%
  • Food & beverage$11,12888%
  • Education$140%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.5$1,271
Lilly USA, LLC71$1,138
Novo Nordisk48$882
Amgen(2 entities)32$803
AbbVie30$621
Corcept Therapeutics26$547
Medtronic11$386
Boehringer Ingelheim21$385
Dexcom, Inc.14$348
Mannkind Corporation15$331
Radius Health, Inc.14$311
Xeris Pharmaceuticals, Inc.15$300
Insulet Corporation13$288
Tandem Diabetes Care, Inc.12$284
GSK4$281
Inspire Medical Systems, Inc.2$272
Sanofi-aventis U.S. LLC13$263
AstraZeneca(2 entities)12$237
Novartis12$231
Bayer10$200
Recordati_rare_diseases_inc.8$195
Neurocrine Biosciences, Inc.6$171
Endo Pharmaceuticals Inc.9$171
Endo USA, Inc.8$167
Abbott8$163
Cequr Corporation4$158
Averitas Pharma Inc.8$140
Mylan Specialty L.p.1$125
Kowa Pharmaceuticals America, Inc.1$125
Amphastar Pharmaceuticals, Inc.6$116
Sanofi1$106
Antares Pharma, Inc.5$100
BETA Bionics, Inc.5$99
Takeda Pharmaceuticals U.S.A., Inc.5$98
Otsuka America Pharmaceutical, Inc.1$91
Intuity Medical Inc4$69
Madrigal Pharmaceuticals2$67
Vapotherm Inc1$66
Amneal Pharmaceuticals LLC3$66
Coloplast1$56
Kyowa Kirin, Inc.3$56
IBSA Pharma Inc.3$54
Ascendis Pharma Endocrinology Inc2$52
Esperion Therapeutics, Inc.3$52
Almatica Pharma LLC2$45
Halozyme Inc2$43
Eisai Inc.2$40
Pfizer2$39
Tolmar, Inc.2$36
Soleno Therapeutics, Inc.1$33
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$32
Embecta Corp.1$31
Acella Pharmaceuticals, LLC2$31
Currax Pharmaceuticals LLC2$31
Rhythm Pharmaceuticals, Inc.1$30
Zealand Pharma US, Inc.1$25
EUSA Pharma (US) LLC1$23
Vivus LLC1$22
E.r. Squibb & Sons, L.L.C.1$21
GRT US Holding, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,576 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$24,130
Medicare patients
136
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide334$559,999
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog58$186,609
Tresiba Flextouch U-200Insulin Degludec86$158,306
MounjaroTirzepatide98$141,817
TrulicityDulaglutide62$113,316
Synjardy XrEmpagliflozin/Metformin Hcl82$109,482
Tresiba Flextouch U-100Insulin Degludec122$107,698
JardianceEmpagliflozin48$63,886
FarxigaDapagliflozin Propanediol43$50,579
Xigduo XrDapaglifloz Propaned/Metformin35$43,811
Humalog Kwikpen U-200Insulin Lispro11$34,245
Evenity (2 Syringes)Romosozumab-Aqqg13$32,785
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$30,851
Lyumjev Kwikpen U-100Insulin Lispro-Aabc29$30,214
Repatha SureclickEvolocumab25$26,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$882$559,999334 claims
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$1,138$256,411171 claims
Boehringer IngelheimSynjardy Xr, Jardiance$385$173,368130 claims
AstraZenecaFarxiga$237$50,57943 claims
AmgenEvenity (2 Syringes)$803$32,78513 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$66$3,366301 claims
AbbVieSynthroid$621$2,65559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →